☆ 4.6 Review

Reshaping the Pancreatic Cancer Microenvironment at Different Stages with Chemotherapy

CANCERS (2023)

Related references

Note: Only part of the references are listed.

Article Surgery

Surgical Decision-Making in Pancreatic Ductal Adenocarcinoma Modeling Prognosis Following Pancreatectomy in the Era of Induction and Neoadjuvant Chemotherapy

Joseph R. Habib et al.

Summary: This study aimed to develop a predictive model of oncologic outcomes for patients with PDAC undergoing resection after neoadjuvant or induction chemotherapy. By analyzing data from 581 patients, it was found that the type of chemotherapeutic used and the number of chemotherapy cycles received preoperatively were associated with overall survival (OS) and recurrence-free survival (RFS). Other factors contributing to survival models included tumor grade, histopathologic response to therapy, nodal status, and administration of adjuvant chemotherapy. The validated models had concordance indices of 0.68 and 0.65 for OS and RFS, respectively.

ANNALS OF SURGERY (2023)

Add to Collection

Article Oncology

Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma

Manoj Amrutkar et al.

Summary: This study examines the effects of neoadjuvant chemotherapy (NAT) on the tumor and systemic metabolism in pancreatic ductal adenocarcinoma (PDAC), using comparative proteomic profiling. NAT-treated tumors showed lower expression of metabolic proteins, and patients who underwent NAT had reduced serum lactate and high-density lipoprotein-cholesterol. Furthermore, chemoresistant cancer cells expressed higher cancer stem cell markers, both in vivo and in vitro.

MOLECULAR ONCOLOGY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Chemotherapy-induced tumor immunogenicity is mediated in part by megakaryocyte-erythroid progenitors

Avital Vorontsova et al.

Summary: Chemotherapy not only kills tumor cells directly but also enhances T cell-mediated anti-tumor immunity, and the effects of chemotherapy on immature immune cells have not been studied. Through a mouse pancreatic cancer model, it was found that gemcitabine chemotherapy increased the number of immature bone marrow cells, and transplanting these cells reduced tumor growth and increased anti-tumor immune cells. This effect is dependent on the secretion of CCL5 and CXCL16 by MEPs.

ONCOGENE (2023)

Add to Collection

Article Surgery

Why the Treatment Sequence Matters Interplay Between Chemotherapy Cycles Received, Cumulative Dose Intensity, and Survival in Resected Early-stage Pancreas Cancer

Victoria S. Wu et al.

Summary: The completion of recommended chemotherapy cycles and cumulative relative dose intensity have a significant impact on the survival of patients with resected pancreatic ductal adenocarcinoma. Neoadjuvant chemotherapy plays a positive role in increasing the likelihood of patients receiving recommended cycles and higher dose intensity.

ANNALS OF SURGERY (2023)

Add to Collection

Article Multidisciplinary Sciences

Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment

Gregor Werba et al.

Summary: The tumor microenvironment (TME) in pancreatic ductal adenocarcinoma (PDAC) plays a crucial role in tumor progression. In this study, single-cell RNA sequencing was performed on PDAC samples before and after chemotherapy. The results showed a heterogeneous mixture of cancer cell subtypes and distinct fibroblast and macrophage subpopulations. Interestingly, chemotherapy did not cause a shift towards a different cancer cell subtype, but rather impacted the ligand-receptor interactions, suggesting a potential role in promoting resistance to immunotherapy.

NATURE COMMUNICATIONS (2023)

Add to Collection

Article Oncology

The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma

Kenji Kawahara et al.

Summary: The optimal regimens of neoadjuvant chemotherapy (NAC) and its modification of the tumor microenvironment (TME) in patients with borderline resectable pancreatic ductal adenocarcinoma (BR PDAC) are still unknown. This study found that stromal remodeling by NAC affects recurrence patterns and prognosis in BR PDAC patients, with low stromal ratio being associated with early liver metastasis and high Ki-67 levels.

CLINICAL & EXPERIMENTAL METASTASIS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression

Carolina F. Ruivo et al.

Summary: This study reveals that pancreatic ductal adenocarcinoma (PDAC) tumors establish a communication network mediated by cancer stem cells (CSC) and the protein agrin, which promotes tumor growth and therapy resistance. CSC release extracellular vesicles (EVs) that activate specific proteins, leading to increased tumor cell proliferation and transcriptional regulator activation. Targeting this communication network may provide a potential strategy for targeted therapy and has significant implications for cancer stem cells.

GUT (2022)

Add to Collection

Article Gastroenterology & Hepatology

Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis

Gaia Bellomo et al.

Summary: This study investigates the reaction of the microenvironment in PDAC liver metastases to chemotherapy and its role in metastatic disease progression after treatment. The researchers found that chemotherapy induces infiltration of proinflammatory macrophages and activates cytotoxic T cells in the liver, but after treatment, neutrophils are recruited to the liver and promote tumor cell regrowth. Disruption of neutrophil infiltration or inhibition of the Gas6/AXL signaling axis in combination with chemotherapy inhibits metastatic growth.

GUT (2022)

Add to Collection

Article Biochemistry & Molecular Biology

A New Oxadiazole-Based Topsentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells

Camilla Pecoraro et al.

Summary: CDK1 plays a crucial role in pancreatic ductal adenocarcinoma and is one of the main causes of chemoresistance. A new compound that inhibits cell growth and induces apoptosis while targeting CDK1 has been discovered in this study.

MOLECULES (2022)

Add to Collection

Article Oncology

Early Tumor-Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer

Ryul Kim et al.

Summary: This study investigates the effects of chemotherapy on the tumor-immune microenvironment (TME) in gastric cancer patients. They found that chemotherapy can remodel the TME, leading to increased infiltration of natural killer (NK) cells, repolarization of macrophages, and increased antigen presentation. However, nonresponders to chemotherapy exhibited different features, including low or absent expression of PD-L1, increased WNT signaling, B-cell infiltration, and increased expression of LAG3 in T cells coupled with decreased dendritic cell abundance.

CANCER DISCOVERY (2022)

Add to Collection

Review Oncology

Macrophage and Neutrophil Interactions in the Pancreatic Tumor Microenvironment Drive the Pathogenesis of Pancreatic Cancer

Hillary G. Pratt et al.

Summary: The survival rates for patients with pancreatic adenocarcinoma are extremely low due to late detection and lack of effective treatments. Immunotherapy, a potential treatment method, has shown limited progress in pancreatic adenocarcinoma. This review explores the roles of macrophages and neutrophils as prominent immune cell types in the pancreatic tumor environment and how they impact the harsh tumor environment and standard of care therapies. Targeting macrophages and neutrophils could potentially improve outcomes for patients with pancreatic adenocarcinoma.

CANCERS (2022)

Add to Collection

Article Oncology

HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation

Maria Serena Roca et al.

Summary: This study investigated the potential of domatinostat in sensitizing PDAC to standard chemotherapeutic treatment. The results showed that domatinostat can enhance the sensitivity of PDAC to chemotherapy drugs by targeting cancer stem cells and inducing oxidative stress. Mechanistically, domatinostat reduces the expression and function of FOXM1, a transcription factor involved in stemness and DNA repair. The expression of FOXM1 is also correlated with the prognosis of chemotherapy-treated PDAC patients.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

TGFβ selects for pro-stemness over pro-invasive phenotypes during cancer cell epithelial-mesenchymal transition

Yutaro Tsubakihara et al.

Summary: TGF beta promotes sternness and invasiveness in breast cancer cells by inducing epithelial-mesenchymal transition (EMT) and metastatic colonization by inducing mesenchymal-epithelial transition (MET). However, whether TGF beta can promote both sternness and invasiveness simultaneously via EMT remains unclear.

MOLECULAR ONCOLOGY (2022)

Add to Collection

Review Oncology

Exosomes and their roles in the chemoresistance of pancreatic cancer

Yubin Pan et al.

Summary: Pancreatic cancer is a highly lethal malignancy, and there is an intrinsic connection between chemoresistance and exosomes in the tumor microenvironment.

CANCER MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy

Jiaqi Yang et al.

Summary: This study reveals two different stages of immunosuppression in the development of pancreatic ductal adenocarcinoma (PDAC), with early stage characterized by abundant Tregs and late stage featuring myeloid suppressive cells. Depletion of PD-L1 and targeting Arg1(+) macrophages effectively triggered anti-tumor immunity, prolonged survival, and generated PDAC-specific immune memory.

EBIOMEDICINE (2022)

Add to Collection

Article Oncology

Targeting Proliferating Tumor-Infiltrating Macrophages Facilitates Spatial Redistribution of CD8+ T Cells in Pancreatic Cancer

Xiaobao Yang et al.

Summary: This study suggests that targeting proliferating tumor-infiltrating macrophages may increase CD8(+) cytotoxic lymphocyte (CTL) infiltration and facilitate the spatial redistribution of CD8(+) T cells in tumors, contributing to the antitumor effect.

CANCERS (2022)

Add to Collection

Article Multidisciplinary Sciences

Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer

Jorge Luis Galeano Nino et al.

Summary: The study investigates the interactions between tumor-associated microbiota and host cells in oral squamous cell carcinoma and colorectal cancer using in situ spatial-profiling technologies and single-cell RNA sequencing. The results show that the distribution of microbiota within the tumor is highly organized in microniches with immune and epithelial cell functions, promoting cancer progression.

NATURE (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Focal adhesion kinase priming in pancreatic cancer, altering biomechanics to improve chemotherapy

Kendelle J. Murphy et al.

Summary: The dense desmoplastic and fibrotic stroma in pancreatic ductal adenocarcinoma (PDAC) plays a role in disease progression and treatment response. Reciprocal interactions between the tumor and stroma through integrin-mediated signaling, particularly Focal Adhesion Kinase (FAK), are important in regulating stromal remodeling and tissue stiffness. Targeting the PDAC stroma, including transient stromal manipulation via short-term FAK inhibition, may enhance the vulnerability of PDAC cells to chemotherapy. This article highlights the significance of treatment timing and suggests further exploration of anti-fibrotic therapies for PDAC and other fibrotic diseases.

BIOCHEMICAL SOCIETY TRANSACTIONS (2022)

Add to Collection

Article Genetics & Heredity

Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment

William L. Hwang et al.

Summary: This study provides a high-resolution molecular landscape of pancreatic ductal adenocarcinoma (PDAC) using single-nucleus RNA sequencing and whole-transcriptome digital spatial profiling. It identifies recurrent expression programs in malignant cells and fibroblasts, including a newly identified neural-like progenitor malignant cell program associated with poor prognosis. The study also reveals three multicellular communities with distinct contributions from malignant, fibroblast and immune subtypes. This refined molecular and cellular classification can guide clinical trials and therapeutic targeting for specific cellular phenotypes and multicellular interactions.

NATURE GENETICS (2022)

Add to Collection

Article Medicine, Research & Experimental

Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer

Max Heiduk et al.

Summary: This study found that neoadjuvant chemotherapy can increase the density of T cells within the tumor and alter the cytokine production. This suggests that combining immunotherapy with neoadjuvant regimens may improve treatment outcomes and prognosis of pancreatic cancer.

JCI INSIGHT (2022)

Add to Collection

Article Oncology

Dysregulated FOXM1 signaling in the regulation of cancer stem cells

Gulab Sher et al.

Summary: Since the introduction of the cancer stem cell paradigm, significant progress has been made in understanding the role of cancer stem cells (CSCs) in tumor biology, including metastasis and drug resistance. The transcription factor FOXM1 has emerged as a key regulator of CSCs, involved in their formation, maintenance, and functionality. This review summarizes the evidence for the mechanisms by which FOXM1 promotes stemness in different types of cancers and highlights its prognostic importance.

SEMINARS IN CANCER BIOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers

Tom Van Nyen et al.

Summary: Metabolic reprogramming is associated with cancer development and therapy resistance. In this study, the downregulation of serine biosynthesis enzyme PHGDH in a subset of patients is shown to be associated with relapse in platinum-treated ovarian cancers, as well as upregulation of NAD(+) and PARP activity. These findings reveal metabolic vulnerabilities with clinical implications for a subset of platinum-resistant ovarian cancers.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Cell Biology

SHMT2-mediated mitochondrial serine metabolism drives 5-FU resistance by fueling nucleotide biosynthesis

Erica Pranzini et al.

Summary: The study reveals that alterations in serine metabolism affect the sensitivity of colorectal cancer cells to 5-FU. Resistant cells become dependent on serine by increasing its synthesis or uptake. Mitochondrial compartmentalization of one-carbon metabolism supports purine biosynthesis and DNA damage response in resistant cells.

CELL REPORTS (2022)

Add to Collection

Article Oncology

Serum levels of IL-6 and CRP can predict the efficacy of mFOLFIRINOX in patients with advanced pancreatic cancer

Feifei Shen et al.

Summary: This study identified IL-6 and CRP levels as valuable biomarkers for predicting survival outcomes in mPC patients treated with mFOLFIRINOX. High IL-6 levels were associated with poor progression and shorter PFS. Increases in IL-6 and CRP levels during chemotherapy correlated with disease progression. The combination of IL-6 and CRP levels helped predict treatment outcomes.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Avital Klein-Brill et al.

Summary: This study compared the two common first-line treatments for metastatic adenocarcinoma of the pancreas, FOLFIRINOX and gemcitabine plus nab-paclitaxel, and found that FOLFIRINOX was associated with improved overall survival and fewer posttreatment complications.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Oncology

Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer

Andressa Dias Costa et al.

Summary: This study investigates the impact of neoadjuvant chemotherapy on the tumor immune microenvironment in pancreatic ductal adenocarcinoma. The findings suggest that neoadjuvant chemotherapy can shift the immune microenvironment towards an anti-tumorigenic state and improve patient survival.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Genetics & Heredity

Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer

Daniel Cui Zhou et al.

Summary: This multi-omic analysis of pancreatic cancer identified spatially resolved, heterogeneous cell populations and revealed treatment-related changes in communication between tumor and stromal cells. The study provides a deeper understanding of the substructure of pancreatic ductal adenocarcinoma and may contribute to improved therapy for patients with this disease.

NATURE GENETICS (2022)

Add to Collection

Article Multidisciplinary Sciences

PD-L1-directed PlGF/VEGF blockade synergizes with chemotherapy by targeting CD141+ cancer-associated fibroblasts in pancreatic cancer

Duk Ki Kim et al.

Summary: Chemotherapy-induced fibrosis in PDAC is elucidated and a combinatorial therapeutic strategy for desmoplastic cancers is highlighted.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Multidisciplinary Sciences

Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer

Lea Monteran et al.

Summary: This study found that systemic treatment with doxorubicin following resection of triple-negative breast tumors induces the expression of complement factors in lung fibroblasts and modulates an immunosuppressive metastatic niche, thus promoting lung metastasis. Targeting complement signaling with pharmacological treatment can alleviate immune dysregulation and reduce lung metastasis.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Biology

Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized pancreatic cancer: A hybrid clinical-preclinical study

Iago de Castro Silva et al.

Summary: This study investigates the predictive role of neutrophil-to-lymphocyte ratio (NLR) in pancreatic cancer chemotherapy, and discovers that combining NLR-attenuating anti-Ly6G with chemotherapy can improve pathologic response and survival, potentially by suppressing inflammatory cancer-associated fibroblast (CAF) polarization and chemoresistant signaling.

ELIFE (2022)

Add to Collection

Article Surgery

Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival

Woohyung Lee et al.

Summary: This study showed that decreased metabolic parameters of PET/CT after neoadjuvant chemotherapy were associated with improved survival and recurrence-free survival. Large delta values were related to a positive impact on recurrence. Post-neoadjuvant chemotherapy SUVmax >= 3 was an independent prognostic factor for negative impact on survival.

BRITISH JOURNAL OF SURGERY (2022)

Add to Collection

Article Surgery

Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer

Mark J. Truty et al.

Summary: This study aimed to identify predictive factors associated with operative morbidity, mortality, and survival outcomes in patients with BR/LA PDAC undergoing TNT. The results showed that independent factors associated with favorable survival outcomes in resected patients include extended duration chemotherapy, optimal post-chemotherapy CA19-9 response, and major pathologic response. Complete metabolic response highly correlated with major pathologic response in a subset of patients.

ANNALS OF SURGERY (2021)

Add to Collection

Article Oncology

Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy

Theodoros Michelakos et al.

Summary: This study evaluated the immune response induced by neoadjuvant therapy in PDAC patients. The findings suggest that neoadjuvant FOLFIRINOX may lead to immunologically relevant changes in the tumor microenvironment, reducing HLAA defects, increasing CD8(+) cell density, and decreasing T regulatory cell and M2 macrophage density.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Add to Collection

Article Oncology

Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer

Zongting Gu et al.

Summary: PDAC is a solid malignant tumor with a low operative rate and poor prognosis, with gemcitabine chemotherapy being one of the main treatment options. However, the efficacy of gemcitabine therapy is limited due to gemcitabine resistance, which may be influenced by the fibrotic tumor microenvironment and metabolic remodeling in PDAC. Targeting the tumor microenvironment may be a key strategy to overcome gemcitabine resistance and improve patient outcomes.

CANCER LETTERS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Spatially confined sub-tumor microenvironments in pancreatic cancer

Barbara T. Grunwald et al.

Summary: Through large-scale integration of histology-guided regional multiOMICs with clinical data and patient-derived preclinical models, we identified distinct subTMEs in the human pancreatic tumor microenvironment (TME) that are linked to tumor immunity, subtypes, differentiation, and treatment response. Reactive subTMEs rich in coordinated fibroblast communities were immune hot, while matrix-rich deserted subTMEs harbored fewer activated fibroblasts but showed chemoprotective features. These subTMEs originated in fibroblast differentiation trajectories and produced patient-specific heterogeneity tightly linked to malignant biology.

CELL (2021)

Add to Collection

Article Gastroenterology & Hepatology

Zinc-Dependent Regulation of ZEB1 and YAP1 Coactivation Promotes Epithelial-Mesenchymal Transition Plasticity and Metastasis in Pancreatic Cancer

Mingyang Liu et al.

Summary: The study revealed that ZIP4 activates ZEB1 and YAP1 to regulate pancreatic cancer metastasis and EMT plasticity, with significant impact on tumor progression and spread.

GASTROENTEROLOGY (2021)

Add to Collection

Article Oncology

Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer

Hui Peng et al.

Summary: The study demonstrates that FOLFIRINOX has a significant impact on the immune system of patients with PDAC, by enhancing effector T cells and downregulating suppressor cells. This suggests that neoadjuvant therapy with FOLFIRINOX may improve immune therapy and clinical outcomes in patients with PDAC.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Multidisciplinary Sciences

Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis

Xu Wang et al.

Summary: A subset of immunosuppressive P2RX1-negative neutrophils accumulate in the liver metastases of pancreatic ductal adenocarcinoma (PDAC), expressing increased levels of immunosuppressive molecules such as PD-L1 and having enhanced mitochondrial metabolism. The upregulation of the transcription factor Nrf2 in P2RX1-deficient neutrophils is associated with PD-L1 expression and metabolic reprogramming, contributing to the evasion of antitumor immunity by metastatic PDAC tumors.

NATURE COMMUNICATIONS (2021)

Add to Collection

Letter Surgery

Neoadjuvant Chemotherapy in Pancreatic Cancer

Thomas Hank et al.

JAMA SURGERY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages

Remi Samain et al.

Summary: The study suggests that SOM230 has the potential to be an effective anti-metastatic therapy in PDA by regulating stromal activities, reducing inflammatory responses, and improving the immunosuppressive tumor microenvironment. This pharmacotherapy shows promise in reshaping the tumor environment and enhancing treatment outcomes for pancreatic cancer patients.

CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts

Huiqin Liu et al.

Summary: CAFs play a critical role in the PDAC tumor microenvironment, promoting cancer proliferation, metastasis, and resistance. Designing drug delivery systems to target PDAC CAFs poses challenges due to the heterogeneity and multifaceted biological roles of CAFs, requiring a careful balance in targeting different types of CAFs.

ADVANCED DRUG DELIVERY REVIEWS (2021)

Add to Collection

Article Oncology

Characterisation of circulating tumour cell phenotypes identifies a partial-EMT sub-population for clinical stratification of pancreatic cancer

Alexander Semaan et al.

Summary: DEP-FFF was used to isolate CTCs in PDAC patients, revealing four distinct sub-populations including pEMT-CTCs, which were correlated with disease progression, survival, and recurrence. This highlights the importance of immunophenotyping and quantifying specific CTC sub-populations in PDAC.

BRITISH JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer

Satoshi Okubo et al.

Summary: The study found that the count of CD204+ macrophages in the cancer cell nest of PDAC patients after NACRT is an independent predictor of early disease recurrence, while NACRT decreases overall immune cell counts. Although the counts of CD4+ T cells, CD20+ B cells, and Foxp3+ T cells were significantly decreased in the immune cell-rich tumor stroma in the NACRT group, there was no significant difference in the cancer cell nest.

CANCER SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status

Kendelle J. Murphy et al.

Summary: In this study, transient manipulation of focal adhesion kinase in PDAC was visualized using intravital fluorescence imaging, with real-time quantification of cell cycle reporter to improve chemotherapy response. Analysis of different matrices and environmental cues helped to reduce PDAC metastasis.

SCIENCE ADVANCES (2021)

Add to Collection

Article Cell Biology

Stabilized epithelial phenotype of cancer cells in primary tumors leads to increased colonization of liver metastasis in pancreatic cancer

Julienne L. Carstens et al.

Summary: The study indicates that partial epithelial to mesenchymal transition is associated with metastasis in pancreatic ductal adenocarcinoma (PDAC), and genetic suppression can lead to epithelial stabilization and increased liver metastasis.

CELL REPORTS (2021)

Add to Collection

Article Oncology

Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial

Monika Graeser et al.

Summary: The study found that changes in immune infiltrate in breast cancer patients before and after NACT treatment can impact the pathological complete response rate, with a transition from "cold" to "hot" immune cell composition potentially increasing the pCR rate of PD1-positive CD4 and CD8 cells, while a transition from "hot" to "cold" may decrease the pCR rate of T cells and PD1-positive CD4 cells. Higher pCR rates were associated with an "altered" distribution of T cells and PD1-positive CD4 cells between the tumor and stroma.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Medicine, General & Internal

Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression

Kai Chen et al.

Summary: This study utilized single-cell RNA sequencing to explore the dynamic changes of tumor microenvironment components during PDAC malignant progression, revealing gradual accumulation of immune cells and pancreatic stellate cells. New Treg and exhausted T cell signature genes were identified, and patients with high expression of certain genes had significantly worse prognosis. A new subset of CAFs specific to PDAC, csCAFs, was also discovered.

EBIOMEDICINE (2021)

Add to Collection

Article Oncology

Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma

Mikael oman et al.

Summary: This study investigated the pharmacokinetics of preoperatively administered intraperitoneal 5-FU in patients with resectable PDAC by analyzing levels of 5-FU and metabolites in different tissues. The results showed uptake of 5-FU and drug metabolism to active FdUMP in pancreatic tumor, liver, and lymph nodes, with potential correlations between gene expression and metabolite concentrations. Further studies are needed to evaluate the IP route for 5-FU administration in PDAC patients.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma

Abudureyimu Tuerhong et al.

Summary: Pancreatic ductal adenocarcinoma (PDAC) is characterized by late diagnosis and metabolic reprogramming related to glucose, lipid, and amino acid metabolism, which lead to resistance to chemotherapy. Targeting critical enzymes and/or transporters involved in metabolism may be a promising approach to overcome chemoresistance in PDAC.

CELLULAR AND MOLECULAR LIFE SCIENCES (2021)

Add to Collection

Article Oncology

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

Bruno Bockorny et al.

Summary: This study evaluated the efficacy of dual blockade of CXCR4 and PD1 with chemotherapy in PDAC, showing that the triple combination was safe, well tolerated, and exhibited signs of efficacy in a population with poor prognosis.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Multidisciplinary Sciences

Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade

Sebastian R. Nielsen et al.

Summary: This study demonstrates the potential of lorlatinib in modulating tumor-associated neutrophils and treating PDAC, with preclinical mouse models showing attenuation of PDAC progression by suppressing neutrophil development and recruitment in the tumor microenvironment.

NATURE COMMUNICATIONS (2021)

Add to Collection

Review Oncology

Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC)

Rosa Wijnen et al.

Summary: CDK1 inhibition induces G2/M cell cycle arrest, stimulates apoptosis, and specifically targets CSCs, making it a promising treatment for PDAC. Targeting CDK1 has shown potential for combination therapy with ionizing radiation treatment and conventional chemotherapy, through sensitizing tumor cells and reducing resistance to these treatments. Further research into combination treatments and screening of patients for CDK1 overexpression are essential for optimizing this novel targeted therapy.

CANCERS (2021)

Add to Collection

Article Cell Biology

A single-cell atlas of liver metastases of colorectal cancer reveals reprogramming of the tumor microenvironment in response to preoperative chemotherapy

Li-Heng Che et al.

Summary: Our study utilized single-cell transcriptome analysis to reveal that the TME of treatment-naive tumors is characterized by the higher abundance of less-activated B cells and higher heterogeneity of TAMs. In contrast, tumors treated with PC showed activation of B cells, lower diversity of TAMs with immature and less activated phenotype, lower abundance of dysfunctional T cells and ECM-remodeling cancer-associated fibroblasts, and an accumulation of myofibroblasts. This provides a foundation for future research on cellular mechanisms underlying liver metastasis of CRC and its response to PC.

CELL DISCOVERY (2021)

Add to Collection

Article Ecology

Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer

Andrew Woolston et al.

Summary: Analysis of exome sequencing data from 42 baseline and progression biopsies from cetuximab-treated colorectal cancers reveals limited adaptive mutagenesis but shows a chemotherapy-induced mutational signature that is the main contributor of specific driver mutations that are enriched at acquired resistance.

NATURE ECOLOGY & EVOLUTION (2021)

Add to Collection

Review Oncology

Linking EMT programmes to normal and neoplastic epithelial stem cells

Arthur W. Lambert et al.

Summary: Epithelial stem cells play critical roles in tissue generation, maintenance, and repair, while cancer stem cells are implicated in the growth and recurrence of many carcinomas. The activation of epithelial-mesenchymal transition (EMT) is linked to the formation of both normal and neoplastic stem cells, but the mechanistic basis of this connection remains unclear. Understanding the elusive links between EMT programs and the stem cell state will advance our knowledge of normal stem cell biology and cancer pathogenesis.

NATURE REVIEWS CANCER (2021)

Add to Collection

Article Oncology

Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells

Carmen Mota Reyes et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Gastroenterology & Hepatology

ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells

Mingyang Liu et al.

GASTROENTEROLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy

Ziyu Li et al.

SCIENCE ADVANCES (2020)

Add to Collection

Article Biochemistry & Molecular Biology

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Bruno Bockorny et al.

NATURE MEDICINE (2020)

Add to Collection

Article Surgery

Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma

Giampaolo Perri et al.

JAMA SURGERY (2020)

Add to Collection

Review Oncology

Reshaping the tumor microenvironment: extracellular vesicles as messengers of cancer cells

Bibek Bhatta et al.

CARCINOGENESIS (2020)

Add to Collection

Article Immunology

Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer

Yu Zhang et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2020)

Add to Collection

Review Biochemistry & Molecular Biology

The potential roles of exosomes in pancreatic cancer initiation and metastasis

Wei Sun et al.

MOLECULAR CANCER (2020)

Add to Collection

Article Cell Biology

A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

Monique B. Nilsson et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

Add to Collection

Article Oncology

Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy

Robert M. Samstein et al.

NATURE CANCER (2020)

Add to Collection

Article Oncology

Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study

Ying L. Liu et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Inhibition of protein FAK enhances 5-FU chemosensitivity to gastric carcinoma via p53 signaling pathways

Jingjing Hou et al.

COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2020)

Add to Collection

Article Oncology

Open Sesame?: Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer

Ornella Randazzo et al.

CANCERS (2020)

Add to Collection

Article Medicine, Research & Experimental

Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy

Matthew R. Farren et al.

JCI INSIGHT (2020)

Add to Collection

Article Oncology

The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment

Hongzhi Sun et al.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Small molecule inhibitors in pancreatic cancer

Jufeng Sun et al.

RSC MEDICINAL CHEMISTRY (2020)

Add to Collection

Article Cell Biology

Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma

Junya Peng et al.

CELL RESEARCH (2019)

Add to Collection

Article Pharmacology & Pharmacy

Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC)

Hani M. Babiker et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Chemoresistance in Pancreatic Cancer

Siyuan Zeng et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Add to Collection

Article Multidisciplinary Sciences

Extracellular Vesicles Shedding Promotes Melanoma Growth in Response to Chemotherapy

Luciana Nogueira de Sousa Andrade et al.

SCIENTIFIC REPORTS (2019)

Add to Collection

Article Oncology

Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression

Vincent Bernard et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Gastroenterology & Hepatology

Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma

Timothy M. Nywening et al.

GUT (2018)

Add to Collection

Article Gastroenterology & Hepatology

Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer

E. Hessmann et al.

GUT (2018)

Add to Collection

Article Oncology

FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma

Mashaal Dhir et al.

ANNALS OF SURGICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells

Michael Timaner et al.

CANCER RESEARCH (2018)

Add to Collection

Review Biochemistry & Molecular Biology

Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?

Jente van Staalduinen et al.

ONCOGENE (2018)

Add to Collection

Article Oncology

The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression

Smruti Pushalkar et al.

CANCER DISCOVERY (2018)

Add to Collection

Article Cell Biology

Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer

Lusheng Wei et al.

CELL DEATH & DISEASE (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis

Z. Deng et al.

ONCOGENE (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells

K. E. Richards et al.

ONCOGENE (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Everolimus Inhibits Growth of Gemcitabine-Resistant Pancreatic Cancer Cells via Induction of Caspase-Dependent Apoptosis and G2/M Arrest

Tao Peng et al.

JOURNAL OF CELLULAR BIOCHEMISTRY (2017)

Add to Collection

Article Multidisciplinary Sciences

Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis

Yi Seok Chang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)

Add to Collection

Article Cell Biology

Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism

George S. Karagiannis et al.

SCIENCE TRANSLATIONAL MEDICINE (2017)

Add to Collection

Review Cell Biology

Cancer-derived exosomic microRNAs shape the immune system within the tumor microenvironment: State of the art

Francesca Fanini et al.

SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2017)

Add to Collection

Article Multidisciplinary Sciences

Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer

Julienne L. Carstens et al.

NATURE COMMUNICATIONS (2017)

Add to Collection

Article Oncology

Rho-Associated Protein Kinase (ROCK) Inhibitors Inhibit Survivin Expression and Sensitize Pancreatic Cancer Stem Cells to Gemcitabine

Hiroyuki Takeda et al.

ANTICANCER RESEARCH (2016)

Add to Collection

Article Oncology

Chemotherapy-Induced Inflammatory Gene Signature and Protumorigenic Phenotype in Pancreatic CAFs via Stress-Associated MAPK

Paul A. Toste et al.

MOLECULAR CANCER RESEARCH (2016)

Add to Collection

Article Biochemistry & Molecular Biology

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

Hong Jiang et al.

NATURE MEDICINE (2016)

Add to Collection

Article Oncology

Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy

Russell Hughes et al.

CANCER RESEARCH (2015)

Add to Collection

Article Oncology

Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer

Shintaro Takeuchi et al.

CANCER RESEARCH (2015)

Add to Collection

Article Multidisciplinary Sciences

Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer

Xiaofeng Zheng et al.

NATURE (2015)

Add to Collection

Article Multidisciplinary Sciences

Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance

Kari R. Fischer et al.

NATURE (2015)

Add to Collection

Article Oncology

Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer

Josep Tabernero et al.

ONCOLOGIST (2015)

Add to Collection

Article Oncology

Activation of Vitamin D Receptor Signaling Downregulates the Expression of Nuclear FOXM1 Protein and Suppresses Pancreatic Cancer Cell Stemness

Zhiwei Li et al.

CLINICAL CANCER RESEARCH (2015)

Add to Collection

Article Multidisciplinary Sciences

Slug-Dependent Upregulation of L1CAM Is Responsible for the Increased Invasion Potential of Pancreatic Cancer Cells following Long-Term 5-FU Treatment

Kaja Lund et al.

PLOS ONE (2015)

Add to Collection

Article Oncology

JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells

Shuhei Suzuki et al.

ONCOTARGET (2015)

Add to Collection

Article Oncology

CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models

Yu Zhu et al.

CANCER RESEARCH (2014)

Add to Collection

Article Oncology

Anti-Bv8 Antibody and Metronomic Gemcitabine Improve Pancreatic Adenocarcinoma Treatment Outcome Following Weekly Gemcitabine Therapy

Erez Hasnis et al.

NEOPLASIA (2014)

Add to Collection

Article Oncology

Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses

Jonathan B. Mitchem et al.

CANCER RESEARCH (2013)

Add to Collection

Article Biochemistry & Molecular Biology

An Undesired Effect of Chemotherapy GEMCITABINE PROMOTES PANCREATIC CANCER CELL INVASIVENESS THROUGH REACTIVE OXYGEN SPECIES-DEPENDENT, NUCLEAR FACTOR κB- AND HYPOXIA-INDUCIBLE FACTOR 1α-MEDIATED UP-REGULATION OF CXCR4

Sumit Arora et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2013)

Add to Collection

Article Oncology

Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

Sophie Gourgou-Bourgade et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection

Article Immunology

Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A

Fiorenza Lotti et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2013)

Add to Collection

Article Multidisciplinary Sciences

mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions

Shyuichiro Matsubara et al.

SCIENTIFIC REPORTS (2013)

Add to Collection

Article Oncology

Host Response to Short-term, Single-Agent Chemotherapy Induces Matrix Metalloproteinase-9 Expression and Accelerates Metastasis in Mice

Svetlana Gingis-Velitski et al.

CANCER RESEARCH (2011)

Add to Collection

Article Oncology

Modulation of Pancreatic Cancer Chemoresistance by Inhibition of TAK1

Davide Melisi et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)

Add to Collection

Article Oncology

Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy

David G. DeNardo et al.

CANCER DISCOVERY (2011)

Add to Collection

Article Oncology

CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy

S. Singh et al.

BRITISH JOURNAL OF CANCER (2010)

Add to Collection

Article Oncology

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma

K. K. Y. Cham et al.

BRITISH JOURNAL OF CANCER (2010)

Add to Collection

Review Medicine, General & Internal

Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages

Sonja Gillen et al.

PLOS MEDICINE (2010)

Add to Collection

Article Oncology

Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway

Zhiwei Wang et al.

CANCER RESEARCH (2009)

Add to Collection

Article Gastroenterology & Hepatology

Combined Targeted Treatment to Eliminate Tumorigenic Cancer Stem Cells in Human Pancreatic Cancer

Maria-Theresa Mueller et al.

GASTROENTEROLOGY (2009)

Add to Collection

Article Biochemistry & Molecular Biology

Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines

Wu Huanwen et al.

MOLECULAR CANCER (2009)

Add to Collection

Article Oncology

Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug

Julie Guillermet-Guibert et al.

MOLECULAR CANCER THERAPEUTICS (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.